Cardiorenal relationship: evolution of views
A.A. NASYBULLINA, O.V. BULASHOVA, E.V. KHAZOVA, V.M. GAZIZYANOVA, M.I. MALKOVA
Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012
Nasybullina A.A. — postgraduate student of the Department of Propaedeutics of Internal Diseases, tel. +7-987-267-25-59, e-mail: almed-89@mail.ru
Bulashova O.V. — D. Med. Sc., Professor of the Department of Propaedeutics of Internal Diseases, tel. (843) 296-14-03, e-mail: boulashova@yandex.ru
Khazova E.V. — Cand. Med. Sc., Assistant of the Department of Propaedeutics of Internal Diseases, tel. (843) 236-04-61, e-mail: hazova_elena@mail.ru
Gazizyanova V.M. — resident of the Department of Propaedeutics of Internal Diseases, tel. +7-927-037-73-41, e-mail: violettakoshka2006@rambler.ru
Malkova M.I. — Cand. Med. Sc., Assistant of the Department of Propaedeutics of Internal Diseases, tel. +7-960-051-61-16, e-mail: marimalk@yandex.ru
This review considers the definition of the term «cardiorenal relationships» in patients with cardiovascular disease, including heart failure. Interest in this scientific problem is caused by the uncertainty of such frequent term in publications as «kidney damage», when it is not clear, whether it means independent (primary) kidney disease or secondary damage in chain of the cardiovascular continuum. As a response to this question there was formulated understanding of the term «cardiorenal syndrome». In the development of this problen, the Russian society of cardiology has made an attempt to unite all possible pathological conditions of kidneys which can occur in cardiac patients, in a certain classification scheme, which makes it necessary to develop common approaches to the management of patients with cardiovascular and kidney disease.
Key words: cardiorenal syndrome, cardiovascular disease, chronic kidney disease.
REFERENCES
- Matsushita K., Velde M., Astor V.S. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010, vol. 375, pp. 2073-2081.
- Ronco C., Mc Cullouqh P., Anker S.D. et al. Cardio-renal syndromes: report from consensus conference of acute dialysis quality initiative. Eur Heart J, 2010, vol. 31 (6), pp. 703-711.
- Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histologic changes found in renal biopsy specimens from patients with persistent glomerulonephritis. Lancet, 1968, vol. 2 (7564), pp. 363-366.
- Arutyunov G. P., Oganezova L. G. Tubulointerstitial renal unit and its defeat in hypertension. Klinicheskaya Nefrologiya, 2011, no. 1, pp. 52-57 (in Russ.).
- Kriz W., Le Hir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int, 2005, vol. 67 (2), pp. 404-419.
- Kutyrina I.M., Shvetsov M.Yu. Possibilities of treatment of renal hypertension. Quality of life. Meditsina, 2006, no. 4 (15), pp. 78-89 (in Russ.).
- K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis, 2002, vol. 39, (suppl. 2), pp. 1-266.
- Moss N.G., Colinders R.E., Gottschalk CW. Neural control of renal function. In Windhager E. E. «Renal physiology». NY, Oxford University Press, 1992. Chapter 22.
- Arutyunov G. P. Pathophysiological processes in the kidneys in patients with chronic heart failure Heart failure. Serdechnaya nedostatochnost’, 2008, no. 9 (5), pp. 234-250 (in Russ.).
- Ridao N., Luno J., Garcia de Vinuesa S. et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant, 2001, vol. 16 (suppl. l), pp. 70-73.
- Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens, 2009, vol. 27 (11), pp. 2121-2158.
- Chertow G.M., Soroko S.H., Paganini E.P. et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int, 2006, vol. 70, pp. 1120-6.
- Scheen A.J. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol, 2013, vol. 9 (5), pp. 529-550.
- Tomilina N.A. The problem of cardiovascular disease in chronic renal failure. Nefrol. i dializ, 2003, no. 1, pp. 15-24 (in Russ.).
- Beddhu S., Allen-Brady K., Cheung A. et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int, 2002, vol. 62, pp. 1776-83.
- Sorensen C.R., Brendorp V., Rask-Madsen C. et al. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur. Heart J, 2002, vol. 23, pp. 948-952.
- Kuz’min O. B. Mechanisms of development and progression of nephropathy in patients with chronic heart failure, cardiorenal syndrome. Nefrologiya, 2011, no. 15 (2), pp. 20-29 (in Russ.).
- Klein I.H., Ligtenberg G, Oey P.L. et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol, 2001, vol. 12, pp. 2427-2433.
- Tokmakova M.P., Skali H., Kenchaiah S. et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation, 2004, vol. 110, pp. 3667-3673.
- Fonarow S.C., Stough W.G., Abraham W.T. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Soll Cardiol, 2007, vol. 50, pp. 768-777.
- Stevens L.A., Coresh J., Greene T. et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med, 2006, vol. 354, pp. 2473-2483.
- Matsushita K., Mahmodi B.K., Woodward M. et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation forest mated glomerular filtration rate. JAMA, 2012, vol. 307, pp. 1941-1951.
- Smirnov A.V., Shilov E.M., Dobronravov V.A. et al. National guidelines. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. Nefrologiya, 2012, vol. 16, no.1, pp. 89-115 (in Russ.).
- Parving H.H. Initiation and progression of diabetic nephropathy. N Engl J Med, 1996, vol. 335, pp. 1682-1683.
- Jager A., Kostense P.J., Ruhe H.G. et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vac Biol, 1999, vol. 19, pp. 617-624.
- Gerstein H.C., Mann J.F., Yi Q. et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA, 2001, vol. 286, pp. 421-426.
- Redon J., Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens, 2002, vol. 20, pp. 353-355.
- Wachtell K., Ibsen H., Olsen M.H. et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med, 2003, vol. 139, pp. 901-906.
- de Leeuw P.W., Ruilope L.M., Palmer C.R. et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med, 2004, vol. 164, pp. 2459-2464.
- Arnlov J., Evans J.C., Meigs J.B. et al. Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation, 2005, vol. 112, pp. 969-975.
- National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kid Dis, 2004, vol. 43 (suppl. 1), pp. 16-33.